Gilead hungry for 'don't eat me' cancer biotech: reports

Gilead hungry for 'don't eat me' cancer biotech: reports

Source: 
Fierce Biotech
snippet: 

A new decade, the same old game: It’s time to play, who will Gilead buy? Sources now says it’s Forty Seven, a cancer-focused startup with a unique MOA.